The week in health tech, explained in plain English.Get the free newsletter →
November 18, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Optum to Sell New York Physician Practices to 2 Health Systems

Optum is offloading physician practice assets in New York, selling to New Hyde Park-based Northwell Health and Valhalla-based Westchester Medical Center, according to regulatory filings cited by Becker's Hospital Review.

Northwell's Lenox Hill Hospital will acquire assets from Optum Medical Care, formerly CareMount Medical, along with CareMount Health Solutions and ProHealth Medical Management. All three sit under UnitedHealth Group, the parent company that has spent years building Optum into one of the largest employers of physicians in the country. The sale marks a reversal in a market Optum aggressively consolidated, acquiring CareMount and ProHealth to anchor its Northeast footprint.

For patients and clinicians, the change means new ownership and administrative control of practices that have already swapped hands once. For the industry, it signals that UnitedHealth is willing to prune underperforming or non-core physician assets even as it remains the dominant force in care delivery. Regional systems like Northwell and Westchester Medical Center stand to expand their ambulatory reach in the competitive New York market.

More in Finance

Finance

Versant and Lilly Back $100M Gene Therapy Startup

Versant Ventures, Eli Lilly, and other investors are putting $100 million into a new startup built to solve one of gene therapy's thorniest challenges.

Why it matters: Major capital targeting gene therapy's core delivery and durability problems could unlock a new wave of treatments if the platform works.

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.